Prognostic Value of biomarkers hsCRP and NT-proBNP in patients with myocardial infarction
Biomarkers hsCRP and NT-proBNP in myocardial infarction
Keywords:
Myocardial infarction, Acute Coronary Syndrome, Prognostic Biomarker, high sensitivity C- reactive protein, Interleukin- 6.Abstract
Background: To evaluate whether serum interleukin-6 (IL-6) and highly sensitive c reactive protein is associated with preferred predictor for risk factor associated to Myocardial Infarction.
Aim: The aim of this study was to investigate the Interleukin 6 and high sensitivity C-reactive protein (hsCRP) levels in patients with Myocardial Infarction.
Materials and methods: Total numbers of 50 subjects Myocardial Infarction patients were included. hsCRP by immunoturbidimetry method, Interleukin 6 estimation was carried out by sandwich ELISA Method, The inclusion of age group was between 25 to 74 years. Statistical analysis was done by using SPSS, version 21.0. p values were calculated by Quartile ratio, ANOVA unpaired t-test and Kaplan-Meier Curve Method. The p<0.05 was considered statistically significant. All participants had completed questionnaire, physical examination, Present/Past Medical History, and laboratory assessment.
Results: The cross-sectional study, Demographic and baseline characteristic of Quartile group of IL-6 and hsCRP are significant (p value= ˂0.001). Lipid profile correlated with quartile ratio association between IL-6 and hsCRP are significant (p value= ˂0.001). IL-6 and hsCRP were each associated participants observed via Kaplan-Meier method with significantly of Quartile 25% vs 40% and Overall comparison of biomarkers (Log rank) chi square test (IL-6= 12.80 p-value= 0.005 vs hsCRP= 7.24 p- value= 0.064).
Conclusion: Our study shows that high levels of hsCRP and IL-6 may be used as diagnostic information that provided by the predictable Acute Myocardial Infarction.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Sanjeev Kumar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.